Methicillin Resistant Staphylococcus Aureus (MRSA)
Conditions
Interventions
Pharmaceutical Form: Cutaneous solution
Sponsors
The University of Manchester
Central Manchester and Manchester Children's University Hospital NHS Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Type 1 or 2 diabetes Age 18-75 Active foot ulceration Prsence of significant neuropathy: Vibration Perception Threshold > 25 volts and Neuropathy Disability Score >3/10 MRSA isolated from the active ulcer site on two consecutive specimens Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Presence of peripheral vascular disease requiring urgent surgical management Wounds in which the MRSA is the primary infecying organism rather than colonisation Known history of poor medical compliance Wounds requiring systemic antibiotic treatment Anti-coagulant therapy Patients who do not consent Pregnant or breastfeeding women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The eradication of MRSA in diabetic foot ulcers;Secondary Objective: Time to eradication Mechanism of action of larvae in eradicating MRSA;Primary end point(s): Eradication of MRSA from colonized diabetic foot ulcers | — |
Countries
United Kingdom
Outcome results
None listed